Inhibikase Therapeutics IKT
NASDAQ IKT
$1.66 -0.05 (-2.63%)
As of: Oct 21, 2026 · 3:51 PM EDT

Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2021)

Updated

Inhibikase Therapeutics' Non-Current Debt came in at $248,911 for Q2 2021, unchanged from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Non-Current Debt (2020 - 2021) Analysis & Trends

At the end of FY2020, Inhibikase Therapeutics' Non-Current Debt was $276,461.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,138.83 Bn 1,107.41 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 618.88 Bn 537.41 Bn 17.26 Bn 37.34 Bn
3 AbbVie 502.93 Bn 476.04 Bn 12.70 Bn 62.48 Bn
4 Merck 369.61 Bn 323.99 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 298.70 Bn 262.69 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 261.35 Bn 235.03 Bn 12.86 Bn 23.68 Bn
7 Amgen 237.59 Bn 192.99 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 191.60 Bn 165.79 Bn 6.22 Bn 23.83 Bn
9 Pfizer 170.23 Bn 116.88 Bn 10.94 Bn 60.50 Bn
10 Inhibikase Therapeutics 288.92 Mn -296.56 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 248,911.00
Sep 30, 2021 248,911.00
Jun 30, 2021 248,911.00
Mar 31, 2021 1.49 Mn
Dec 31, 2020 595,456.00
API Access

Inhibikase Therapeutics Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=IKT&period=max&api_key=YOUR_API_KEY